News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
89,117 Results
Type
Article (15626)
Company Profile (103)
Press Release (73388)
Section
Business (15226)
Career Advice (290)
Deals (4236)
Drug Delivery (13)
Drug Development (11641)
Employer Resources (15)
FDA (1980)
Job Trends (2079)
News (33576)
Policy (3325)
Tag
Academia (867)
Allergies (21)
Alliances (3032)
Alzheimer's disease (325)
Approvals (2004)
Artificial intelligence (24)
Bankruptcy (41)
Best Places to Work (1535)
Biotechnology (70)
Breast cancer (50)
Cancer (299)
Cardiovascular disease (35)
Career advice (254)
CAR-T (22)
Cell therapy (40)
Clinical research (8929)
Collaboration (56)
COVID-19 (616)
Data (349)
Diabetes (41)
Diagnostics (836)
Drug pricing (20)
Earnings (5149)
Events (7032)
Executive appointments (38)
FDA (2111)
Funding (55)
Gene therapy (27)
GLP-1 (128)
Government (590)
Healthcare (2670)
Infectious disease (631)
Inflammatory bowel disease (29)
Interviews (45)
IPO (2800)
Job creations (618)
Job search strategy (211)
Layoffs (51)
Legal (665)
Lung cancer (56)
Lymphoma (17)
Medical device (1685)
Medtech (1685)
Mergers & acquisitions (1495)
Metabolic disorders (97)
Neuroscience (388)
NextGen: Class of 2025 (876)
Non-profit (750)
Northern California (254)
Obesity (52)
Opinion (47)
Parkinson's disease (17)
People (5443)
Pharmaceutical (23)
Phase I (2061)
Phase II (3391)
Phase III (3779)
Pipeline (83)
Postmarket research (670)
Preclinical (1653)
Press Release (32)
Radiopharmaceuticals (21)
Rare diseases (46)
Real estate (710)
Regulatory (2353)
Research institute (674)
Resumes & cover letters (43)
Southern California (185)
Startups (339)
United States (2100)
Vaccines (94)
Weight loss (45)
Date
Today (24)
Last 7 days (92)
Last 30 days (280)
Last 365 days (3909)
2025 (570)
2024 (4077)
2023 (4334)
2022 (7060)
2021 (8715)
2020 (8207)
2019 (5910)
2018 (4696)
2017 (4128)
2016 (4406)
2015 (5387)
2014 (3911)
2013 (3345)
2012 (3451)
2011 (3561)
2010 (3101)
Location
Africa (122)
Asia (4629)
Australia (1076)
California (539)
Canada (191)
China (64)
Connecticut (28)
Delaware (21)
Europe (11883)
Florida (73)
Georgia (19)
Illinois (50)
Indiana (44)
Japan (26)
Maryland (40)
Massachusetts (387)
Minnesota (53)
Missouri (20)
New Jersey (171)
New York (210)
North Carolina (96)
Northern California (254)
Pennsylvania (129)
South America (137)
Southern California (185)
Texas (54)
Virginia (22)
Washington State (56)
89,117 Results for "wall street journal".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer reported that third-quarter revenue and adjusted profit beat the analysts’ consensus.
October 29, 2024
·
2 min read
·
Greg Slabodkin
Earnings
Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal
Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.
October 30, 2024
·
2 min read
·
Heather McKenzie
Business
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its rivals, according to
The Wall Street Journal
.
October 22, 2024
·
2 min read
·
Tristan Manalac
Business
Pfizer’s 2024 Outlook Disappoints Wall Street, Plans $500M in Additional Cost Cuts
The biopharma giant provided full-year 2024 guidance on Wednesday that fell below Wall Street’s expectations, as it continues a cost-cutting effort now up to $4 billion in total.
December 13, 2023
·
2 min read
·
Tyler Patchen
Earnings
Despite Near 30% Drop in Humira Sales, AbbVie Beats Wall Street’s Q2 Revenue Expectations
While Humira sales were impacted by cheaper biosimilars, AbbVie reported in its second-quarter earnings results Thursday that revenues jumped nearly 45% for Skyrizi and almost 56% for Rinvoq year over year, respectively.
July 25, 2024
·
2 min read
·
Tyler Patchen
Earnings
Gilead Beats Q2 Wall Street Estimates on Strong HIV, Cancer, Liver Disease Sales
Gilead Sciences’ liver disease portfolio delivered surprisingly robust performance in the second quarter, jumping 17% as the company awaits next week’s potential FDA approval of seladelpar in primary biliary cholangitis.
August 9, 2024
·
2 min read
·
Tristan Manalac
Earnings
AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira
AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance demonstrated the overall strength of its immunology franchise.
October 31, 2024
·
2 min read
·
Tristan Manalac
Earnings
Pfizer, Merck Beat Wall Street Expectations Amid Strong Biopharma Q2 Earnings Season
Second-quarter revenues were better than analysts expected as
Merck reported 16% growth for its blockbuster cancer treatment Keytruda, while Pfizer benefited from its ongoing cost-cutting efforts and sales of its COVID-19 antiviral Paxlovid.
July 30, 2024
·
2 min read
·
Tyler Patchen
Drug Pricing
FTC to Sue ‘Big Three’ PBMs for Setting Insulin, Other Drug Prices: WSJ
The Federal Trade Commission plans to file lawsuits against the three largest pharmacy benefit managers over allegedly steering patients away from less expensive drugs, according to The Wall Street Journal.
July 11, 2024
·
2 min read
·
Tristan Manalac
Earnings
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
November 6, 2024
·
3 min read
·
Tristan Manalac
1 of 8,912
Next
